argenx NV ADR (ARGX) - Stock Price & Dividends

Argenx NV ADR (NASDAQ: ARGX) is a biotechnology company that focuses on developing therapies for autoimmune diseases. The company is based in Amsterdam, the Netherlands, with operations also in the United States, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy.

Their leading product candidate is efgartigimod, which targets various conditions such as myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and other autoimmune disorders. Argenx is also working on several other products like ARGX-109, ARGX-116, and ARGX-118 for different autoimmune and inflammatory conditions.

Furthermore, Argenx has strategic partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, as well as collaborations with various institutions and companies like NYU Langone Health, Leiden University Medical Center, and Genmab A/S for developing therapeutic antibodies for immunology and oncology.

The company's dedication to advancing treatments for autoimmune diseases and its extensive network of collaborations showcase its commitment to improving patients' lives. For more information, you can visit their website at https://www.argenx.com.